Inflammatory biomarkers in type 2 diabetic patients: Effect of glycemic control and impact of ldl subfraction phenotype

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Vinagre, Irene ^a,b   Sánchez Quesada, José L ^c   Sánchez Hernández, Juan ^d   Santos, David ^c,d   Ordoñez Llanos, Jordi ^a,b,c   De Leiva, Alberto ^a,e   Pérez, Antonio ^a,d  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Adiponectin; Atherogenic dyslipidemia; C reactive protein; Inflammatory biomarkers; LDL phenotype; Monocyte chemotactic protein 1; Transforming growth factor 1; Tumor growth factor 1; Type 2 diabetes

Indexed keywords

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCEMIC INDEX; HUMANS; INFLAMMATION MEDIATORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 84893189199     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-34     Document Type: Article

References (42)

1. Eschwege E. The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications. Diabetes Metab 2003, 29(4 Pt 2):6S19-6S27.
2. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000, 67(3):291-300. 10.1016/S0024-3205(00)00622-6, 10983873.
3. Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay JL, Rentfro A, McCormick JB, Fisher-Hoch SP. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine+ 2012, 57(1):136-142. 3270578, 22035595.
4. Azar ST, Salti I, Zantout MS, Major S. Alterations in plasma transforming growth factor beta in normoalbuminuric type 1 and type 2 diabetic patients. J Clin Endocrinol Metab 2000, 85(12):4680-4682.
5. Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, Costantino F, Ruotolo G, Luzi L, Perseghin G. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 2003, 26(10):2883-2889. 10.2337/diacare.26.10.2883, 14514596.
6. Sell H, Eckel J. Monocyte chemotactic protein-1 and its role in insulin resistance. Curr Opin Lipidol 2007, 18(3):258-262. 10.1097/MOL.0b013e3281338546, 17495598.
7. Serban M, Tanaseanu C, Kosaka T, Vidulescu C, Stoian I, Marta DS, Tanaseanu S, Moldoveanu E. Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus. J Cell Mol Med 2002, 6(4):643-647. 10.1111/j.1582-4934.2002.tb00462.x, 12611648.
8. Calle MC, Fernandez ML. Inflammation and type 2 diabetes. Diabetes Metab 2012, 38(3):183-91. 10.1016/j.diabet.2011.11.006, 22252015.
9. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102(1):42-47. 10.1161/01.CIR.102.1.42, 10880413.
10. Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S, Luben R, Bingham S, Khaw KT, Wareham NJ. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 2009, 52(6):1040-1047. 10.1007/s00125-009-1338-3, 19326095.
11. Nakano S, Kuboki K, Matsumoto T, Nishimura C, Yoshino G. Small, dense LDL and high-sensitivity C-reactive protein (hs-CRP) in metabolic syndrome with type 2 diabetes mellitus. J Atheroscler Thromb 2010, 17(4):410-415. 10.5551/jat.1891, 20197633.
12. Suzuki H, Sakamoto M, Hayashi T, Iuchi H, Ohashi K, Isaka T, Sakamoto N, Kayama Y, Tojo K, Yoshimura M, Utsunomiya K. Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol 2013, 12:71. 10.1186/1475-2840-12-71, 3663745, 23635096.
13. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002, 87(2):563-568. 10.1210/jcem.87.2.8249, 11836286.
14. Wagner AM, Sanchez-Quesada JL, Benitez S, Bancells C, Ordonez-Llanos J, Perez A. Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. Diabetes Res Clin Pract 2011, 93(1):e25-e28. 10.1016/j.diabres.2011.03.009, 21440948.
15. Belalcazar LM. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care 2010, 33(11):2297-303. 10.2337/dc10-0728, 2963483, 20682679.
16. Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003, 166(2):387-394. 10.1016/S0021-9150(02)00371-4, 12535753.
17. Rodriguez-Moran M, Guerrero-Romero F. Increased levels of C-reactive protein in noncontrolled type II diabetic subjects. J Diabetes Complications 1999, 13(4):211-215. 10.1016/S1056-8727(99)00047-1, 10616861.
18. Pickup JC, Mattock MB, Crook MA, Chusney GD, Burt D, Fitzgerald AP. Serum sialic acid concentration and coronary heart disease in NIDDM. Diabetes Care 1995, 18(8):1100-1103. 10.2337/diacare.18.8.1100, 7587844.
19. Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 2009, 302(11):1186-1194. 10.1001/jama.2009.1347, 19755697.
20. Takebayashi K, Aso Y, Inukai T. Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes. Methods 2004, 53(6):693-699.
21. Sanchez-Quesada JL, Vinagre I, Juan-Franco E, Sanchez-Hernandez J, Blanco-Vaca F, Ordonez-Llanos J, Perez A. Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution. Am J Cardiol 2012, 110(1):67-71. 10.1016/j.amjcard.2012.02.051, 22481012.
22. Sanchez-Quesada JL, Vinagre I, de Juan-Franco E, Sanchez-Hernandez J, Bonet-Marques R, Blanco-Vaca F, Ordonez-Llanos J, Perez A. Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes. Cardiovasc Diabetol 2013, 12:112. 10.1186/1475-2840-12-112, 3750253, 23915379.
23. Sanchez-Quesada JL, Benitez S, Otal C, Franco M, Blanco-Vaca F, Ordonez-Llanos J. Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects. J Lipid Res 2002, 43(5):699-705.
24. Baars T, Konorza T, Kahlert P, Mohlenkamp S, Erbel R, Heusch G, Kleinbongard P. Coronary aspirate TNFalpha reflects saphenous vein bypass graft restenosis risk in diabetic patients. Cardiovasc Diabetol 2013, 12:12. 10.1186/1475-2840-12-12, 3560373, 23305356.
25. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007, 30(5):1200-1205. 10.2337/dc06-2416, 17322479.
26. Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, Xiao X, Shan ZL, Zhang Y, Yao P, Liu LG. Inflammatory Markers and Risk of Type 2 Diabetes: A systematic review and meta-analysis. Diabetes Care 2013, 36(1):166-175. 10.2337/dc12-0702, 3526249, 23264288.
27. Festa A, D'Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51(4):1131-1137. 10.2337/diabetes.51.4.1131, 11916936.
28. Bertoni AG, Burke GL, Owusu JA, Carnethon MR, Vaidya D, Barr RG, Jenny NS, Ouyang P, Rotter JI. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010, 33(4):804-810. 10.2337/dc09-1679, 2845031, 20097779.
29. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003, 26(6):1745-1751. 10.2337/diacare.26.6.1745, 12766104.
30. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler, Thromb, Vasc Biol 1999, 19(4):972-978. 10.1161/01.ATV.19.4.972, 10195925.
31. Sciarretta S, Ferrucci A, Ciavarella GM, De PP, Venturelli V, Tocci G, De BL, Rubattu S, Volpe M. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens 2007, 20(7):784-791. 10.1016/j.amjhyper.2007.01.023, 17586414.
32. Nakhjavani M, Esteghamati A, Asgarani F, Khalilzadeh O, Nikzamir A, Safari R. Association of oxidized low-density lipoprotein and transforming growth factor-beta in type 2 diabetic patients: a cross-sectional study. Transl Res 2009, 153(2):86-90. 10.1016/j.trsl.2008.11.009, 19138653.
33. Di BE, Campagnolo P, Margariti A, Zampetaki A, Karamariti E, Hu Y, Xu Q. Endothelial lineage differentiation from induced pluripotent stem cells is regulated by microRNA-21 and transforming growth factor beta2 (TGF-beta2) pathways. J Biol Chem 2013, [Epub ahead of print].
34. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002, 45(6):805-812. 10.1007/s00125-002-0829-2, 12107724.
35. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27(3):813-823. 10.2337/diacare.27.3.813, 14988310.
36. Astrup A, Finer N. Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'?. Obes Rev 2000, 1(2):57-59. 10.1046/j.1467-789x.2000.00013.x, 12119987.
37. Isono M, Mogyorosi A, Han DC, Hoffman BB, Ziyadeh FN. Stimulation of TGF-beta type II receptor by high glucose in mouse mesangial cells and in diabetic kidney. Am J Physiol Renal Physiol 2000, 278(5):F830-F838.
38. Koppel H, Riedl E, Braunagel M, Sauerhoefer S, Ehnert S, Godoy P, Sternik P, Dooley S, Yard BA. L-carnosine inhibits high-glucose-mediated matrix accumulation in human mesangial cells by interfering with TGF-beta production and signalling. Nephrol Dial Transplant 2011, 26(12):3852-3858. 10.1093/ndt/gfr324, 21750159.
39. Lim AK, Tesch GH. Inflammation in diabetic nephropathy. Mediators Inflamm 2012, 2012:146154. 3432398, 22969168.
40. Loeffler I, Wolf G. Transforming growth factor-beta and the progression of renal disease. Nephrol Dial Transplant 2013, 2013:2013.
41. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?. Diabetes 2000, 49(9):1399-1408. 10.2337/diabetes.49.9.1399, 10969821.
42. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000, 58(1):293-301. 10.1046/j.1523-1755.2000.00165.x, 10886574.